{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:38:08Z","timestamp":1792093088300,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.blre.2025.101298","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T19:02:10Z","timestamp":1745607730000},"page":"101298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies"],"prefix":"10.1016","volume":"73","author":[{"given":"Mohamed","family":"Yassin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Alkindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateen","family":"Ata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Qari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer","family":"Altooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Capellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0005","article-title":"Recent advances in sickle-cell disease therapies: A review of Voxelotor, Crizanlizumab, and L-glutamine","volume":"10","author":"Migotsky","year":"2022","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.blre.2025.101298_bb0010","first-page":"133","article-title":"Genotypic and phenotypic composition of sickle cell disease in the Arab population - A systematic review","volume":"16","author":"Ata","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101298_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101298_bb0020","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the global burden of disease study 2021","volume":"10","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101298_bb0025","doi-asserted-by":"crossref","first-page":"3885979","DOI":"10.1155\/2022\/3885979","article-title":"Sickle cell disease in children and adolescents: A review of the historical, clinical, and public health perspective of sub-Saharan Africa and beyond","volume":"2022","author":"Egesa","year":"2022","journal-title":"Int J Pediatr"},{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2022.103555","article-title":"Sickle cell disease in the new era: advances in drug treatment","volume":"61","author":"Lee","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2025.101298_bb0035","author":"EMA"},{"issue":"3","key":"10.1016\/j.blre.2025.101298_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101298_bb0045","first-page":"2017","article-title":"FDA approves new treatment for sickle cell disease","author":"USFDA","year":"2017","journal-title":"FDA News Release"},{"key":"10.1016\/j.blre.2025.101298_bb0050","series-title":"FDA approves crizanlizumab-tmca for sickle cell disease","author":"USFDA","year":"2019"},{"key":"10.1016\/j.blre.2025.101298_bb0055","series-title":"FDA approves voxelotor for sickle cell disease","author":"USFDA","year":"2019"},{"key":"10.1016\/j.blre.2025.101298_bb0060","series-title":"FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years","author":"USFDA","year":"2021"},{"key":"10.1016\/j.blre.2025.101298_bb0065","series-title":"Revocation of authorisation for sickle cell disease medicine Adakveo","author":"Agency","year":"2023"},{"key":"10.1016\/j.blre.2025.101298_bb0070","first-page":"142","article-title":"Efficacy, safety, and biomarker analysis of 5 mg and 7.5 Mg doses of Crizanlizumab in patients with sickle cell disease: primary analyses from the phase III STAND study","author":"Abboud","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101298_bb0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-025-06216-1","article-title":"A review on disease modifying pharmacologic therapies for sickle cell disease","volume":"104","author":"Mahadevia","year":"2025","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101298_bb0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of Voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101298_bb0085","article-title":"Real-world data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients","volume":"9","author":"Elenga","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.blre.2025.101298_bb0090","doi-asserted-by":"crossref","first-page":"1243870","DOI":"10.3389\/fmed.2023.1243870","article-title":"Real-world observational study on the long-term effect of L-glutamine treatment on renal parameters of adult and pediatric patients with sickle cell disease","volume":"10","author":"Elenga","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.blre.2025.101298_bb0095","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.21873\/invivo.12889","article-title":"Pediatric patients with sickle cell disease at a public hospital: nutrition, compliance and early experience with L-glutamine therapy","volume":"36","author":"Gotesman","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.blre.2025.101298_bb0100","first-page":"134","article-title":"L-glutamine decreases opioid use in individuals with sickle cell disease and chronic pain: A case series","author":"Wilson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126666","article-title":"Barriers to the use of Endari\u2122 in an urban adult sickle cell center","volume":"134","author":"Ogu","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101298_bb0115","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2022008209","article-title":"Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease","volume":"7","author":"Kanter","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101298_bb0120","series-title":"Safety and efficacy of CRIZANLIZUMAB in adolescents with sickle cell disease (SCD): Initial data from the phase ii","author":"Heeney","year":"2022"},{"key":"10.1016\/j.blre.2025.101298_bb0125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/01.HS9.0000848820.30412.22","article-title":"Real-world incidence of VASO-occlusive crises in patients with sickle cell disease (SCD) and A high baseline disease burden treated with Crizanlizumab: results from A managed access program (map)","volume":"6","author":"Silva Pinto","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.blre.2025.101298_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101298_bb0135","first-page":"132","article-title":"Established prevention of Vaso-occlusive crises with Crizanlizumab is further improved in patients who follow the standard treatment regimen: post-hoc analysis of the phase II Sustain study","author":"Liles","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0140","article-title":"Successful treatment of SCD-related priapism with Crizanlizumab: A case series","volume":"11","author":"Idowu","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"10.1016\/j.blre.2025.101298_bb0145","doi-asserted-by":"crossref","first-page":"2229115","DOI":"10.1080\/16078454.2023.2229115","article-title":"Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report","volume":"28","author":"Afana","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101298_bb0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152362","article-title":"Rare cases of infusion-related reactions (IRRs) presenting as pain events during or after Crizanlizumab infusion in patients (pts) with sickle cell disease (SCD): A systematic evaluation of post-marketing (PM) reports","volume":"138","author":"Kanter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0155","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153136","article-title":"Early evaluation of the use of Crizanlizumab in sickle cell disease: A National Alliance of sickle cell centers study","volume":"138","author":"Kanter","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101298_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29716","article-title":"Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years","volume":"69","author":"Estepp","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101298_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jha2.831","article-title":"Voxelotor improves red blood cell functionality in children with sickle cell anaemia: an ancillary study of the HOPE-KIDS 1 trial","volume":"5","author":"Chonat","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101298_bb0170","series-title":"Compassionate-use VOXELOTOR (GBT440) For patients with severe sickle cell disease (SCD) and LIFE-threatening comorbidities","author":"Blyden","year":"2018"},{"key":"10.1016\/j.blre.2025.101298_bb0175","series-title":"Interim safety and efficacy of voxelotor in children aged 2 to <4 years with sickle cell disease","author":"Fuh","year":"2023"},{"key":"10.1016\/j.blre.2025.101298_bb0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174487","article-title":"Predicting hemoglobin response to hydroxyurea and Voxelotor in adults with sickle cell disease","volume":"142","author":"Saber","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101298_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17474086.2022.2031967","article-title":"Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis","volume":"15","author":"Shah","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101298_bb0190","first-page":"142","article-title":"Real-world experience of individuals with sickle cell disease treated with Voxelotor: initial report from the multicenter, prospective Prospect study","author":"Andemariam","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0195","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153138","article-title":"Real-world experience of Voxelotor for the Management of Complications in sickle cell disease","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101298_bb0205","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-140863","article-title":"Higher hemoglobin levels achieved with Voxelotor are associated with lower Vaso-occlusive crisis incidence: 72-week analysis from the HOPE study","volume":"136","author":"Vichinsky","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153582","article-title":"Long-term safety and efficacy of Voxelotor for patients with sickle cell disease: results from an open-label extension of the phase 3 HOPE trial","volume":"138","author":"Achebe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0215","article-title":"Over 4 years of safety and efficacy with Voxelotor treatment for patients with sickle cell disease: updated results from an open-label extension of the phase 3 HOPE trial","volume":"138","author":"Achebe","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0220","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-140525","article-title":"Real-world effectiveness of Voxelotor for treating sickle cell disease in the US","volume":"136","author":"Zaidi","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101298_bb0225","first-page":"167","article-title":"Real-world effectiveness of voxelotor for the treatment of sickle cell disease","volume":"15","author":"Barcelos","year":"2023","journal-title":"British Journal of. Hematology"},{"key":"10.1016\/j.blre.2025.101298_bb0230","doi-asserted-by":"crossref","first-page":"7533111","DOI":"10.1155\/2023\/7533111","article-title":"Patient-reported experiences in Voxelotor-treated children and adults with sickle cell disease: A Semistructured interview study","volume":"2023","author":"Brown","year":"2023","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0235","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/jim-2021-002215","article-title":"Patient perception of voxelotor treatment benefit in sickle cell disease","volume":"70","author":"Idowu","year":"2022","journal-title":"J Invest Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101298_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18076","article-title":"Voxelotor and albuminuria in adults with sickle cell anaemia","volume":"197","author":"Han","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101298_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26101","article-title":"The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease","volume":"96","author":"Minniti","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101298_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26631","article-title":"Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease","volume":"97","author":"Nagalapuram","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101298_bb0255","first-page":"509","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of Voxelotor (GBT440) in pediatric participants with sickle cell disease (HOPE kids 2)","volume":"381","year":"2019","journal-title":"[Internet]."},{"key":"10.1016\/j.blre.2025.101298_bb0265","series-title":"Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA\u00ae (voxelotor) From Worldwide Markets","author":"Pfizer","year":"2024"},{"key":"10.1016\/j.blre.2025.101298_bb0270","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130802","article-title":"Correlation of Voxelotor exposure with hemoglobin response and measures of hemolysis in patients from the HOPE study","volume":"134","author":"Howard","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0275","article-title":"S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)","volume":"7","author":"Alan Anderson","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101298_bb0280","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2019-126666","article-title":"Barriers to the use of Endari\u2122 in an urban adult sickle cell center","volume":"134","author":"Ogu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101298_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100983","article-title":"Determinants of severity in sickle cell disease","volume":"56","author":"Rees","year":"2022","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.blre.2025.101298_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00191-5","article-title":"Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care","volume":"8","author":"Esoh","year":"2021","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.blre.2025.101298_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/193252","article-title":"Sickle cell disease: new opportunities and challenges in Africa","volume":"2013","author":"Makani","year":"2013","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"10.1016\/j.blre.2025.101298_bb0300","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell Anemia in sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101298_bb0305","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study","volume":"93","author":"Chaturvedi","year":"2018","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101298_bb0310","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2023-186915","article-title":"Patient and parent-reported outcomes post-treatment with Shmir-based lentiviral gene therapy for sickle cell disease","volume":"142","author":"Jimenez-Kurlander","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101298_bb0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/hematology.2021000252","article-title":"Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework","volume":"2021","author":"Badawy","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.blre.2025.101298_bb0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2008.1.177","article-title":"Mechanisms of vasculopathy in sickle cell disease and thalassemia","volume":"2008","author":"Morris","year":"2008","journal-title":"Hematology"},{"issue":"13","key":"10.1016\/j.blre.2025.101298_bb0325","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/bloodadvances.2022009202","article-title":"Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries","volume":"7","author":"Jiao","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T14:26:39Z","timestamp":1755959199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"alternative-id":["S0268960X25000438"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101298","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101298"}}